‘Follow The Money’: Sweden’s Calliditas Plans US Listing
CEO Says NASDAQ Float Will Position Biotech Better Before Pivotal Readout
Sweden’s Calliditas plans a US IPO to better position itself ahead of this year’s pivotal readout of its orphan drug Nefecon in inflammatory renal disease IgA nephropathy.
